Form 4: Cogent Biosciences Director Arlene Morris Granted 44,700 Stock Options

Cogent Biosciences, Inc. Director Arlene Morris was granted 44,700 stock options with an exercise price of $5.64, vesting upon the earlier of the first anniversary of the grant date or the 2026 Annual Meeting of Stockholders.

Summary

• Arlene Morris, a Director of Cogent Biosciences, Inc. (COGT), was granted 44,700 stock options.
• The stock options have an exercise price of $5.64 per share.
• The grant date for these options was June 4, 2025.
• The options are set to expire on June 4, 2035.
• The options will vest in full upon the earlier of June 4, 2026 (the first anniversary of the grant date) or the date of the company's 2026 Annual Meeting of Stockholders.
• Following this transaction, Arlene Morris beneficially owns 44,700 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (stock option grant) which is generally neutral but can be seen as slightly positive due to the alignment of director and shareholder interests.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of executive and director compensation, indicating continuity in governance practices.

Future Outlook

The stock options granted to Director Arlene Morris are subject to a vesting schedule, indicating future potential ownership of common stock upon exercise, contingent on the company's performance and the director's continued service.

Industry Context

The granting of stock options to directors is a common practice across various industries, including biotechnology, as a means of compensation and to align leadership's financial interests with shareholder value creation.

Comparison to Industry Standards

• The practice of granting stock options as part of director compensation is a widely accepted industry standard for aligning director incentives with long-term company performance.
• While the specific number of options (44,700) and exercise price ($5.64) are unique to Cogent Biosciences, the mechanism of a time-based vesting schedule (earlier of one year or next annual meeting) is typical for such grants in the biotechnology sector.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value, potentially leading to more focused efforts on long-term company growth.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The stock options will vest upon the earlier of June 4, 2026, or the date of the 2026 Annual Meeting of Stockholders.
• Upon vesting, the director will have the right to exercise the options to acquire common stock of Cogent Biosciences, Inc. at the specified exercise price.

Key Dates

Keywords

Cogent Biosciences, COGT, Stock Option, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership